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Abstract
Complex diseases are often highly heritable. However, for many complex traits only a small proportion of the heritability can
be explained by observed genetic variants in traditional genome-wide association (GWA) studies. Moreover, for some of
those traits few significant SNPs have been identified. Single SNP association methods test for association at a single SNP,
ignoring the effect of other SNPs. We show using a simple multi-locus odds model of complex disease that moderate to
large effect sizes of causal variants may be estimated as relatively small effect sizes in single SNP association testing. This
underestimation effect is most severe for diseases influenced by numerous risk variants. We relate the underestimation
effect to the concept of non-collapsibility found in the statistics literature. As described, continuous phenotypes generated
with linear genetic models are not affected by this underestimation effect. Since many GWA studies apply single SNP
analysis to dichotomous phenotypes, previously reported results potentially underestimate true effect sizes, thereby
impeding identification of true effect SNPs. Therefore, when a multi-locus model of disease risk is assumed, a multi SNP
analysis may be more appropriate.
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Introduction
Since the first GWA study in 2005[1], hundreds of GWA studies
have been published, reporting more than 2000 associations[2].
However, despite large heritability estimates, relatively few
associations have been reported for most complex traits.
Moreover, associations found in GWA studies often explain only
a small proportion of the phenotypic variation[3]. For example,
although 71 independent loci have been identified as being
associated with Crohn’s Disease, they still account for only 23% of
the estimated heritability[4]. GWA studies of psychiatric diseases
show an even less favorable picture. For instance, schizophrenia
has an estimated heritability of 80%[5,6], but observed genetic
variants currently account for less than 1% of the variance[7].
One explanation of the missing heritability is that complex
diseases are caused by a large number of causal variants with small
effect sizes. Odds ratios (OR) reported in GWA studies are
typically small (i.e., a median OR of 1.33[8]). The many
associations that are tested require a very low significance
threshold to prevent an inflated genome-wide type I error. This
reduces the probability of identifying SNPs with small effect size,
unless sample sizes are large enough to achieve sufficient power to
identify such SNPs. Using large combined datasets within scientific
consortia has significantly increased power in GWA studies.
Despite this increase in power, still only a small number of
associated variants have been identified[3]. A second explanation
of the missing heritability is that risk SNPs are correlated with
unobserved causal genetic variants, since they are unlikely to be
causal themselves[9]. The lower the correlation between an
observed risk SNP and the unobserved causal variant, the smaller
the estimated effect size of the risk SNP, resulting in less explained
variance and hence decreased power. This decrease in power is
most dramatic for rare variants (i.e., SNPs with minor allele
frequencies less than 5% or even 1%) and these variants are less
likely to be tagged by the genotyped SNPs.
The present study addresses a fundamental limitation of
traditional GWA analysis of dichotomous phenotypes which
provides an additional explanation for the difficulty in identifying
effect SNPs and the missing heritability. By definition complex
diseases are caused by numerous risk variants. However, as single
SNP analysis only considers a single SNP at a time, other SNPs
associated with disease can be considered omitted covariates. Gail
et al.[10] proved in the context of generalized linear models that
omitting covariates can result in asymptotically underestimated
effect sizes, even in the absence of confounders. Confounders are
(possibly omitted) covariates that are associated with other
covariates or variables of interest. Gail et al. showed that only
the linear-link and log-link functions produce asymptotically
unbiased effect sizes in generalized linear regression, although
the log-link function can produce asymptotically biased inter-
cepts[10]. In the context of logistic regression, this underestimation
effect reduces the efficiency of effect size statistics[11]. Neuhauss
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and Jewell[12] provided formulas to assess this bias for several
common link functions, including the logit and probit link
functions, which are most suitable for analyzing dichotomous
phenotypes. In linear regression omitting covariates has no effect
on the estimated effect size[11].
The underestimation effect of non-linear link functions can be
best understood in terms of the statistical concept of collapsibility.
Simpson[13] wrote a seminal paper on the surprising non-
equivalence of conditional and marginal odds ratios, which has
later been referred to as Simpsons’s paradox[14,15]. Given three
dichotomous variables X, Y, and Z, he showed that even if the
odds ratios between X and Y conditional on the value of Z are
equal (ORXY jZ~0~ORXY jZ~1~ORXY jZ), this does not imply
that the marginal odds ratios equal the conditional odds ratio
(ORXY~ORXY jZ). In other words, the odds ratio is a non-
collapsible effect measure, as the marginal effect measure (ORXY )
cannot generally be expressed as a weighted average of the
conditional effect measures (ORXY jZ~0 and ORXYjZ~1). In the
context of GWAS, Y is disease status, X is the genotype of an allele
of interest, and Z is the number of risk variants in the genetic
background. In this context Z is unlikely to be dichotomous. An
effect size measure would be called collapsible if the marginal
effect size of SNP X, averaged over all possible genetic
backgrounds Z, can be expressed as a weighted average of all
conditional effect sizes of SNP X (i.e., conditional on specific
genetic background Z).[14,15]
Two conditions have been identified that do result in collapsible
odds ratios[16]. The first condition is that disease status Y and
background Z are independent given SNP X. This implies that
ignoring SNPs which have no effect on disease will not result in
underestimation. The second condition is that SNP X and genetic
background Z are independent given disease status Y. This
situation cannot arise if we (safely) assume that SNPs or the causal
variants with which they are in linkage disequilibrium cause
disease status and not vice versa (see Herna´n et al.[14] for a
discussion on the importance of causal assumptions when dealing
with Simpson’s paradox). In other words, conditional and
marginal odds ratios are only equivalent if the SNP of interest
or the genetic background is not associated with disease status.
Despite the use of the word ‘bias’ by earlier authors[10–12],
Greenland et al. [15] note that non-collapsibility is technically not
a bias. It reflects the mathematical fact that for some effect
measures marginal and conditional effect sizes are non-equivalent.
When choosing a non-collapsible effect size measure, one merely
needs to decide whether the marginal, the conditional effect size or
both are of interest[14]. We believe that in GWA studies the odds
ratio conditional on a fixed genetic background reflects the relative
importance of a single SNP better than the marginal odds ratio. A
single SNP analysis would estimate the marginal odds ratio,
whereas a multi SNP analysis would estimate the odds ratio
conditional on a fixed genetic background. Risk difference and risk
ratio are examples of collapsible effect measures[15]. However, as
traditional GWA analyses are often based on odds ratios, we will
focus here on the logistic or odds disease model.
Complex diseases in GWA studies can be characterized by
numerous risk SNPs with small effect sizes. Although the average
effect size is expected to be small, the variance in the genetic
background increases with the number of true risk SNPs. In the
present simulation study we investigate the potential implications
of non-collapsibility for traditional GWA studies. We first study the
relation between the marginal and the conditional odds ratio
under a naive disease model. The simplicity of the naive model
facilitates the simulation and mathematical analysis of the
underestimation effect. We report how disease characteristics
(e.g., prevalence, number of risk SNPs, minor allele frequency, and
effect sizes) influence the underestimation effect. We also show
how this underestimation affects the estimated explained variance.
Subsequently, we illustrate the underestimation effect under a
more realistic genetic architecture. Finally, we discuss the
implications of underestimating effect size and suggest potential
solutions.
Methods
Modeling a heritable disease requires a function relating
genotype to disease risk. To simulate the implications of traditional
GWA analysis using odds ratios, we constructed a disease
generating model based on the odds model of disease risk. Before
discussing this model in more detail, we illustrate the disease
generating process of the odds model with an example. We assume
that all risk alleles at different loci have equal frequency and equal
effect size (these assumptions have been shown by others to have
little impact on interpretation of results)[17–19]. For example,
Figure 1 shows disease probability and the distribution of risk allele
counts for a disease with a prevalence of 1%, assuming a total
number of 200 effect alleles (i.e., 100 risk SNPs); the odds ratio of
each risk allele is 1.6 and the risk allele frequencies are 0.25. Under
this additive model on the log odds scale, people carry on average
50 risk alleles (binomial mean is 200|0:25) corresponding to a
negligible disease risk. However, as the number of risk alleles
exceeds a threshold, disease probability increases rapidly,
demonstrating the highly non-linear relationship between genetic
risk factors and disease risk. Those at highest risk of disease carry
more risk alleles, w70 in this example, but each affected person
could have a unique portfolio of risk alleles; the effect of a risk
allele on disease depends on the genetic background (other risk
alleles) carried by an individual. The (implicit) error variance in
the odds model is p2=3, the variance of the standard logistic
distribution.
As mentioned before, the marginal odds ratio produced by
single SNP analysis is averaged over all possible genetic
Figure 1. Disease model. Probability of disease as a function of the
number of risk alleles (line) and the distribution of risk alleles in a large
sample (n = 10,000) (histogram). Disease prevalence is 1%. The odds
ratio of each risk SNP is 1.6 and the allele frequencies of risk alleles are
0.25. The maximum number of risk alleles is 200 (i.e., 100 SNPs). The
(implicit) error variance of the odds model is p2=3.
doi:10.1371/journal.pone.0027964.g001
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backgrounds. However, the odds ratios from the odds model,
which we assume generates the disease, are conditional on a fixed
background odds of disease (see section A3.2 in Appendix S1). We
will therefore refer to the conditional odds ratio as the true odds ratio
ORt and to the marginal odds ratio as the (possibly under-)estimated
odds ratio ORe. To relate ORe to the prespecified ORt, we
performed the following four steps: (1) we specified a disease
generating model based on disease characteristics includingORt, (2)
we mathematically derived the genotype distribution of a single SNP
of interest given disease status and disease characteristics, (3) we
repeatedly simulated a case-control sample of the SNP of interest
based on this genotype distribution and computed the corresponding
SNP-based odds ratio (ORe), and (4) we reported the median of all
estimated odds ratios ORe, reflecting the asymptotic marginal odds
ratio estimated by single SNP analysis. We now discuss the disease
generating model.
We specified a disease generating model with four parameters:
(1) disease prevalence pD, (2) true (allelic) odds ratio ORt, (3) minor
allele frequency of risk alleles pa, and (4) the total number of effect
alleles na. Risk alleles can be either minor alleles or major alleles.
We only consider minor risk alleles, as the analysis is analogous for
major risk alleles. Let D be disease status and
z(xa,b0,b1)~b0zb1xa a linear function of the number of risk
alleles xa with effect size b1 and intercept b0. Then the probability
of disease conditional on the number of risk alleles is defined as
(see also Equation S3 in Appendix S1)
P(D~1jXa~xa; b0,b1)~
1
1z exp½{z(xa,b0,b1)"
ð1Þ
As effect size b1 is defined on a log odds scale, exp (b1) is the
effect size on an odds scale. Therefore ORt~ exp (b1) is the true
odds ratio in the biological reality we aim to model.
So far we specified the probability of disease conditional on the
number of risk alleles. To obtain a full probability model of
disease, it is necessary to specify the distribution of risk alleles as
well. Assuming Hardy-Weinberg equilibrium and linkage equilib-
rium for a total of na effect alleles (i.e., twice the number of risk
SNPs) and risk allele frequency pa, the number of risk alleles xa in
the population can be modeled with a binomial distribution
P(Xajna,pa)~
na
xa
! "
pxaa (1{pa)
na{xa ð2Þ
Combining distribution 1 and 2 results in a joint probability
distribution of disease and number of risk alleles given four disease
parameters: risk allele frequency pa, total number of effect alleles
na, effect size b1 on a log odds scale, and intercept b0.
P(D,Xajb0,b1,na,pa)~P(DjXa,b0,b1)P(Xajna,pa) ð3Þ
The probability of disease status P(Djb0,b1,na,pa) can be
obtained by summing over all possible genetic liabilities Xa.
Although b0 has an interpretation as the baseline (or
background) log odds of disease, there is no strong prior
information what this might be, as there is for the other three
model parameters. However, as disease prevalence is an observed
disease characteristic, it is possible to set b0 such that the disease
probability of the model P(D~1jb0,b1,pa,na) equals disease
prevalence pD. Although P(D~1jb0,b1,pa,na)~pD cannot be
solved analytically for b0, an error function, such as the sum
squared error can be defined (Equation S1 in Appendix S1). This
error function can be minimized to obtain a numerical
approximation of b0 that satisfies the equality. Because
ORt~ exp (b1) and number of risk SNPs ns =
1
2 na, the result is a
model of disease with the four parameters: disease prevalence
(pD), true allelic odds ratio (ORt), number of risk SNPs (ns), and
risk allele frequency in risk SNPs (pa). As a fifth parameter, error
variance on the liability trait could be included to model the
proportion of variance explained by all SNPs (heritability), but as
this was not required for the derivations in this paper, we left the
error variance implicit and constant (see section A3.4 in Appendix
S1). From the four-parameter disease model we derived the
genotype distribution of SNP s given disease status and model
parameters P(XsjD,pD,ORt,pa,na) (see Equation S2 in Appendix
S1). Based on this distribution we simulated 10,000 case-control
samples and computed the median estimated SNP-based odds
ratio ORe. By relating the odds ratio ORe obtained when
performing a single SNP analysis to the true odds ratio ORt, we
could study the underestimation effect for different disease
characteristics. Further details on simulation technicalities can be
found in section A1 of Appendix S1.
Although the odds model is mathematically convenient, it
assumes a constant effect size and minor allele frequency for all
risk alleles. Therefore we performed a second simulation
investigating the underestimation effect under a more realistic
genetic architecture. In GWA studies absolute effect sizes on the
log odds scale are roughly exponentially distributed[20,21].
Consequently, effect sizes were drawn from an exponential
distribution with rate parameter 5. This corresponds with an
expected ORt of 1.25, but acknowledges that true effect sizes are
frequently small and rarely large. To avoid rare variants, allele
frequencies were assumed to be uniformly distributed between
0.05 and 0.95. Effect sizes and allele frequencies were drawn once
and fixed in the rest of the simulation replicates. The odds disease
model from the first simulation is easily extended to accommodate
different fixed effect sizes by defining z(xa,b0,b1)~b0zPns
i~1 bixi in Equation 1, where ns is the number of SNPs, bi is
the effect size of SNP i and xi[f0,1,2g refers to the number of risk
alleles at SNP i. The intercept b0was chosen corresponding to a
disease prevalence of 1%.
The asymptotic single SNP estimate was again assessed by
generating 10,000 case-control samples and computing for each
SNP the median odds ratio using a single SNP logistic regression.
Case-control samples, 5000 subjects each, were generated by
repeatedly drawing from the population distribution until 2500
cases and 2500 controls were sampled.
Results
If a disease is caused by a single risk SNP, the odds ratio
estimated by single SNP analysis (ORe) will, on average, reflect the
true odds ratio (ORt) (section A2 in Appendix S1). However, if a
disease is caused by numerous risk SNPs, the median ORe follows
an asymptote. Figure 2 shows the relationship between median
ORe and ORt for diseases caused by 100 risk SNPs with different
prevalences (A) and different minor allele frequencies of the risk
SNPs (B). A wide range of prevalences and minor allele
frequencies results in upper limits for the median SNP-based odds
ratio. This asymptotic effect is more dramatic in diseases with
higher prevalences and/or higher minor allele frequencies.
Depending on the model parameters, the upper bound is reached
with true model odds ratios as low as 1.5. In that case traditional
association testing cannot differentiate, for example, between a
Underestimated Effect Sizes in GWAS
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true odds ratio of 1.5 and a true odds ratio of 3, as both will be
estimated at 1.5, the maximum value that can be obtained. In
other words, under this disease model large true effect sizes are not
identified as such by single SNP association testing.
The asymptotic constraint on the estimated odds ratio is caused
by two factors. First, single SNP odds ratios (ORe) are estimated
across an average over all possible background risks in cases and
controls; this can be seen when computing the conditional
probability of disease status given the genotype at a particular
SNP (section A3.1 in Appendix S1). Only when the risk allele
frequency (pa) approaches zero, the background risk will approach
zero, which is similar to a disease with a single risk SNP. This is
why low risk allele frequencies (for example, pa=0.01) result in a
delayed asymptotic effect compared to high risk allele frequencies
(pa§0:1) (Figure 2B). If the odds ratio for an allele could be
estimated in a subsample of the population that all carried the
same background risk, then the SNP-based odds ratio (ORe)
would (almost) equal the true odds ratio (ORt) (see section A3.2 in
Appendix S1).
Although weighted averaging is part of the explanation of the
constrained odds ratios, it is not a sufficient explanation, because
for continuous phenotypes the asymptotic effect does not occur
when computing SNP-based effect sizes (section A3.3 in Appendix
S1). It is due to the non-collapsibility of the odds ratio that
averaging over background risks results in a discrepancy between
the estimated marginal odds ratio ORe and the true conditional
odds ratio ORt.
A priori the total number of risk SNPs in a disease is unknown,
but it is of course possible to simulate the results of traditional
association testing for diseases with different numbers of risk SNPs.
The asymptotic effect is stronger for diseases which are influenced
by a large number of risk SNPs (Figure 3). In other words, an
increase in the number of SNPs associated with disease results in
increased underestimation. As complex diseases are assumed to be
influenced by many risk SNPs, analyzing numerous large-effect
SNPs with traditional association testing would result in consid-
erable underestimation. This type of underestimation is not due to
a lack of power as increasing sample size will decrease the variance
of effect sizes obtained, but will not reduce underestimation due to
the non-collapsibility of the odds ratio.
We will now show that underestimation of effect sizes can result
in additional missing heritability. Narrow-sense heritability is the
percentage of total phenotypic variance that is explained by
additive genetic variance. Figure 4 compares the explained
variance (on the log odds scale) of true odds models with the
explained variance based on effect sizes obtained from single SNP
association tests. Although many measures of explained variance
exist for logistic regression, we adopted McKelvey-Zavoina’s
pseudo{R2[22], as it is defined on the log odds scale and closely
mirrors the explained variance of continuous traits [23](see section
A3.4 in Appendix S1 for more details on McKelvey-Zavoina’s
pseudo{R2).
McKelvey-Zavoina’s pseudo{R2 strongly depends on the
effect size of risk alleles and the genetic variance in risk SNPs.
Therefore even true odds models show little explained variance in
case of small effect sizes or low minor allele frequencies
(e:g:, pa~0:01). Except for diseases with rare causal variants,
true models with moderate to large effect sizes explain more than
80% of total variance, approaching 100% for very large effect
sizes, indicating large heritability. However, odds models based on
Figure 2. Numerous risk SNPs. Relationship between median estimated SNP-based odds ratio (ORe) and true conditional model odds ratio (ORt)
for a disease with 100 effect SNPs. (A) Different prevalences with risk allele frequency 0.25. (B) Different risk allele frequencies with prevalence 1%.
Simulations are based on a case-control study of 3500 subjects and a 1:1 case:control ratio. Medians are based on 10,000 case-control samples.
doi:10.1371/journal.pone.0027964.g002
Figure 3. Number of risk SNPs. Effect of total number of risk SNPs
on median SNP-based odds ratio (ORe) for different true odds ratios
(ORt). An allele frequency of 0.25 for risk alleles and a prevalence of 1%
is assumed. Simulation is based on a sample of 3500 subjects and a 1:1
case:control ratio. Median is based on 10,000 case-control samples.
doi:10.1371/journal.pone.0027964.g003
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underestimated SNP-based odds ratios (ORe) show a loss in
explained variance compared to odds models based on true effect
sizes (ORt). In the unrealistic case of 100% heritability the typical
loss of explained variance is around 20%. A more realistic disease
with a heritability of 80%, prevalence of 1% and a minor allele
frequency of 50%, still results in an expected loss of more than
10% in explained variance (see Figure 4A). Although prevalence
does not affect the true heritability (dotted line), it does affect the
heritability based on ORe(solid line) (Figure 4B).
Truly associated SNPs are unknown a priori and effect sizes will
be estimated with error. Nonetheless, this analysis shows that even
if truly associated SNPs are known and effect sizes are estimated
without error, traditional association testing on dichotomous
phenotypes can result in a significant loss of explained variance.
The previous results were all based on the assumption of fixed
effect size and allele frequency. Figure 5 shows odds ratios
estimated with single SNP analysis, using a more realistically
simulated data set in which absolute effect sizes are exponentially
distributed and minor allele frequencies are uniformly distributed.
Moderate and large odds ratios are underestimated and the
underestimation effect increases with effect size. For example the
highest risk SNP with a true (conditional) odds ratio of 4.74 has a
marginal odds ratio of 4.36, resulting in underestimation of 9% on
the odds scale. As expected, odds ratios close to one do not show
underestimation. Similar to the naive disease model results,
increasing the average true odds ratio, the number of effect SNPs,
or the prevalence further increases the underestimation effect (data
not shown).
Discussion
Summarizing, our analysis shows a fundamental limitation of
applying single SNP association tests to dichotomous phenotypes.
Single SNP tests can severely underestimate moderate and large
effect sizes for diseases with numerous risk SNPs due to non-
collapsibility of the odds ratio. Therefore the marginal odds ratios
obtained by single SNP tests can be smaller than the true
conditional odds ratios. This underestimation reduces the
explained variance and hence contributes to the missing
heritability. Underestimation is most pronounced in diseases with
high-risk SNPs (i.e., mean ORw1:25), common affect SNPs (i.e.,
MAFw0:1), a large number of risk SNPs (i.e., 100 or more) and
high prevalence (w10%).
Our results are consistent with empirical findings in the GWAS
literature. Odds ratios reported in GWA studies are generally
small[8]. For example, a recent GWA study reported 57 regions
outside the major histocompatibility complex associated with
multiple sclerosis, none of which had an odds ratio much higher
than 1.5 (see Figure 2 in[24]). Although occasionally large effect
Figure 4. Explained Variance. McKelvey-Zavoina’s pseudo{R2 (on log odds scale) as a function of true effect size for an odds model with true
odds ratio (dashed line) and an odds model with median odds ratio obtained by single SNP analyses (solid line) for (A) different risk allele frequencies,
(B) different prevalences, and (C) different number of effect SNPs. Unless stated otherwise models are based on a disease prevalence of 1%, 100 effect
SNPs with risk allele frequencies of 0.25, a case-control sample of 3500 subjects and a 1:1 case:control ratio.
doi:10.1371/journal.pone.0027964.g004
Figure 5. Varying effect sizes. Relationship between median
estimated SNP-based odds ratio (ORe) and true conditional model
odds ratio (ORt) for a disease with 100 effect SNPs and a disease
prevalence of 1%. Effect sizes on log odds scale were drawn once for
each SNP from an exponential distribution with rate parameter 5 and
fixed for all 10,000 case-control simulations. Similarly, allele frequencies
were drawn once for each SNP from a uniform distribution between
0.05 and 0.95 and fixed for all case-control simulations. Case-control
simulation was based on a sample of 5000 subjects and a 1:1
case:control ratio.
doi:10.1371/journal.pone.0027964.g005
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sizes have been reported, numerous common high-risk SNPs have
not been identified for a single dichotomous trait. Searching the
GWAS catalogue (http://www.genome.gov/gwastudies; accessed
August 24, 2011) for SNPs with ORw4 and pv10{8, shows that
no single study reports a disease that is influenced by two or more
common SNPs with ORw4. Diseases for which high odds ratios
are reported for common SNPs (with minor allele frequency in
controls w0:05) include auto-immune diseases such as type I
diabetes (OR~8:3 and OR~5:49)[25,26] and ciliac disease
(OR~7:04)[27]. These high-risk SNPs are part of the major
histocompatibility complex.
Single SNP analysis cannot identify large effect sizes of
numerous risk SNPs, even if many high risk SNPs would exist.
This scenario is mostly of theoretical interest though, as research
on quantitative traits, which are not affected by non-collapsibility,
suggests that numerous high risk SNPs are not likely in practice.
However, conditional odds ratios are likely to be larger than the
marginal odds ratios commonly reported. The significance
thresholds for marginal and conditional odds ratio are equal as
both odds ratios are equivalent in case of no effect[15]. That is,
under the null distribution underestimation is not an issue.
Therefore, underestimation impedes the identification of SNPs
above the significance threshold with underestimated values below
the significance threshold.
GWA studies of diseases with high prevalence have reported less
significantly associated genetic variants than similar studies of
diseases with low prevalence. For example, GWA studies of major
depression disorder, which has a life time prevalence of 15%, have
reported no associations that reached genome-wide significance or
have been solidly replicated[7,28]. On the other hand, studies of
schizophrenia and bipolar disorder, which have life time preva-
lences of 1% or less, have reported several SNPs that did reach
genome-wide significance and/or were replicated[7]. There are
likely to be many factors contributing to the differential success of
GWAS for psychiatric disorders. For example, a lower heritability
for depression compared to schizophrenia could imply smaller effect
sizes under an architecture of the same number of causal variants,
hence requiring larger sample sizes to achieve the necessary power
to detect variants that explain the same proportion of variance.
Nonetheless, the empirical data are consistent with our result that
the underestimation of effect size is larger and the explained
variance in liability is lower for complex diseases with high
prevalence compared to diseases with low prevalence.
The underestimation effect due to non-collapsibility has impor-
tant implications for GWA studies of complex diseases. An
important aim of GWA analyses is to select truly associated SNPs
for use in subsequent analyses and to identify causal variants[19,29].
For selection purposes moderate underestimation of effect sizes need
not be a problem, if sample sizes are large enough. However,
underestimation of effect size requires larger sample sizes to identify
both truly associated SNPs and causal variants. One solution to
avoid underestimation of true effect sizes is to analyze continuous
instead of dichotomous phenotypes, if available. Continuous
phenotypes can usually be modeled with linear regression and
under an additive genetic model SNPs are independent and single
SNP association tests will not result in underestimation. The use of
continuous phenotypes is consistent with the quest for endopheno-
types for complex (psychiatric) diseases[30]. Another solution is to
estimate effect sizes of all SNPs simultaneously rather than
individually. It is for example feasible to estimate the effect sizes
of more than 100,000 SNPs in a single analysis[31]. Based on the
results of Robinson et al.[11], we expect that a multi SNP analysis is
more powerful than a single SNP analysis in the context of a
complex disease. Methods for estimating aggregate statistics such as
explained variance, total number of risk SNPs, and average effect
size of risk SNPs, which analyze all SNPs simultaneously, also
exist[32–34]. Even in the context of continuous traits it might be
beneficial to opt for multi SNP analysis, as adding covariates can
reduce the standard error of the estimates, requiring a smaller
sample size to achieve significance.
There are some limitations to our analysis. First of all, our
conclusions are conditional on simple model assumptions.
However, simpe assumptions do underscore the fundamental
nature of the underestimation effect. A second limitation is that we
have not proved that effect sizes reported in traditional GWA
studies are indeed underestimated. Biases such as the winner’s
curse could also result in overestimation[35,36]. The winner’s
curse refers to the fact that due to stringent multiple testing
correction it is likely that the first significant finding of a SNP will
have a larger effect size than subsequent independent replications.
It is therefore unclear whether in practice reported odds ratios are
overestimated or underestimated. The major difference between
the underestimation effect we discuss and the winner’s curse bias,
is that the latter will decrease as the sample size increases, whereas
non-collapsibility results in a fundamental underestimation that is
not affected by sample size. Finally, although we show that
underestimation can partly explain missing heritability, this effect
could be modest. Continuous traits such as human height are not
affected by the underestimation effect, but also show missing
heritability[37].
In conclusion, single SNP association testing on dichotomous
phenotypes can be problematic. Our analysis implies that odds
ratios typically reported in GWA studies [8] could be underesti-
mates of the true conditional odds ratios. We argue that
asymptotic underestimation is a serious draw-back, as it cannot
be remedied by increasing sample size. We therefore recommend
analyzing all SNPs simultaneously. As a variety of multi SNP
methods have been proposed in the literature, we are currently
comparing the performance of several of those on real GWAS
data.
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